Press Releases Tiziana Life Sciences Ltd

Equities

TLSA

BMG889121031

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.7801 ^USD	-7.25%		+17.13%	+39.30%

Apr. 23	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
Apr. 23	Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MEDIA: MS News Today: Foralumab found to ease fatigue in SPMS patients in access program	Apr. 25	PU
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	Apr. 25	AQ
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program	Apr. 23	AQ
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today	Apr. 22	AQ
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program	Apr. 22	AQ
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	Apr. 19	AQ
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®	Apr. 19	AQ
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	Apr. 11	AQ
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease	Mar. 05	AQ
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients	Jan. 08	AQ
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024	Jan. 05	AQ
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation	Jan. 05	AQ
Tiziana Life Sciences : Updated Interim Results for the Six Months Ended 30 June 2023 - Form 6-K	Dec. 29	PU
Tiziana Life Sciences : Interim Results for the Six Months Ended 30 June 2023 863.7 KB	Dec. 29	PU
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis	Dec. 19	AQ
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar	Dec. 04	AQ
Tiziana Life Sciences : Notice of Annual General Meeting of Shareholders on Thursday 14th December 2023 at 8.30am EST/ 1.30pm UK - Form 6-K	Dec. 01	PU
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis	Nov. 30	AQ
Tiziana Life Sciences : Notice of Annual General Meeting December 2023	Nov. 23	PU
Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023	Nov. 01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Tiziana Life Sciences Ltd

Equities

TLSA

BMG889121031

Press Releases

Filters